WO2024008121A1 - Composés azabicyclo difluoro-substitués et leurs utilisations - Google Patents
Composés azabicyclo difluoro-substitués et leurs utilisations Download PDFInfo
- Publication number
- WO2024008121A1 WO2024008121A1 PCT/CN2023/105913 CN2023105913W WO2024008121A1 WO 2024008121 A1 WO2024008121 A1 WO 2024008121A1 CN 2023105913 W CN2023105913 W CN 2023105913W WO 2024008121 A1 WO2024008121 A1 WO 2024008121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- present
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 182
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- 229910052740 iodine Inorganic materials 0.000 claims description 53
- 229910052794 bromium Inorganic materials 0.000 claims description 52
- 229910052801 chlorine Inorganic materials 0.000 claims description 52
- 229910052731 fluorine Inorganic materials 0.000 claims description 51
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 40
- 125000003282 alkyl amino group Chemical group 0.000 claims description 39
- 125000004076 pyridyl group Chemical group 0.000 claims description 28
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 125000004414 alkyl thio group Chemical group 0.000 claims description 26
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 25
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 25
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 24
- 125000002883 imidazolyl group Chemical group 0.000 claims description 19
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 113
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 112
- 239000000243 solution Substances 0.000 description 90
- 238000006243 chemical reaction Methods 0.000 description 81
- -1 Azinyl Chemical group 0.000 description 58
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000000460 chlorine Substances 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 38
- 239000012043 crude product Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 229910001868 water Inorganic materials 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000011534 incubation Methods 0.000 description 21
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- 238000003756 stirring Methods 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 11
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000003706 Complement factor D Human genes 0.000 description 9
- 108090000059 Complement factor D Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 230000002503 metabolic effect Effects 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 7
- 230000004154 complement system Effects 0.000 description 7
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 7
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000012224 working solution Substances 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 210000001589 microsome Anatomy 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000012089 stop solution Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ANDWKDRELVPNDM-UHFFFAOYSA-N 6-bromo-3-methylpyridin-2-amine Chemical compound CC1=CC=C(Br)N=C1N ANDWKDRELVPNDM-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000003228 microsomal effect Effects 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 229960005371 tolbutamide Drugs 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 229960001632 labetalol Drugs 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 2
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 2
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 2
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000009390 immune abnormality Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 2
- 229960000203 propafenone Drugs 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- OCXAGXCMZACNEC-CTWZREHQSA-N (1R,3S,5R)-2-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound C(C)(=O)C1=NN(C2=CC=C(C=C12)C=1C=NC(=NC=1)C)CC(=O)N1[C@@H]2C[C@@]2(C[C@H]1C(=O)NC1=NC(=CC=C1C)Br)C OCXAGXCMZACNEC-CTWZREHQSA-N 0.000 description 1
- BTJLWJOEZRVRNL-UHFFFAOYSA-N (2-methylpyrimidin-5-yl)boronic acid Chemical compound CC1=NC=C(B(O)O)C=N1 BTJLWJOEZRVRNL-UHFFFAOYSA-N 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DZJCKZLDOYQXMW-UHFFFAOYSA-N 1-(2-methylpropoxyperoxy)butane Chemical compound C(CCC)OOOCC(C)C DZJCKZLDOYQXMW-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- OBZRGWKVWAXNKZ-UHFFFAOYSA-N 2-bromo-5-methylpyrazine Chemical compound CC1=CN=C(Br)C=N1 OBZRGWKVWAXNKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CMZODOCHMREYBB-UHFFFAOYSA-N 5-bromo-2-methylpyridine-3-carbonitrile Chemical compound CC1=NC=C(Br)C=C1C#N CMZODOCHMREYBB-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- YWTWJLZYZLZQFZ-UHFFFAOYSA-N 6-bromo-3-chloropyridin-2-amine Chemical compound NC1=NC(Br)=CC=C1Cl YWTWJLZYZLZQFZ-UHFFFAOYSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- NBALYPYUMLGQIW-UHFFFAOYSA-N BrC1=CC=C(C(=N1)N)F Chemical compound BrC1=CC=C(C(=N1)N)F NBALYPYUMLGQIW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- LOGUAPASTBWDAO-UHFFFAOYSA-M [NH4+].[K+].OC([O-])=O.OC([O-])=O Chemical compound [NH4+].[K+].OC([O-])=O.OC([O-])=O LOGUAPASTBWDAO-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-M difluoroacetate Chemical compound [O-]C(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a series of difluoro-substituted azabicyclic compounds and their applications, specifically to the compounds represented by formula (V) and their pharmaceutically acceptable salts.
- Complement is a group of proteins with enzymatic activity present in the serum and tissue fluid of humans or vertebrate animals.
- the complement system is part of the innate immune system and plays an important role in the body's resistance to infections such as foreign pathogens, bacteria and parasites.
- the complement system is also an important component of the connection between innate immunity and adaptive immunity.
- the activation response of the complement system undergoes a series of fine adjustments in the body to maintain the dynamic balance of complement activation and inactivation, thereby preventing excessive consumption of complement components and damage to own tissues. Therefore, abnormal activation of complement can lead to various immune abnormalities.
- Complement consists of plasma proteins, including soluble proteins, membrane-bound proteins and complement receptors. It is mainly produced by membrane proteins expressed in the liver or cell surface and plays a role in plasma, tissues or cells.
- the complement system is mainly activated through three pathways: the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP).
- Complement factor D (Factor D) is located at the front end of the bypass pathway of the complement system. By inhibiting complement factor D, it selectively inhibits the bypass pathway without interfering with the classical complement pathway and the lectin pathway. It can treat diseases related to immune abnormalities without increasing infections. risk. There are currently no small molecule Factor D inhibitors on the market.
- Alexion’s factor D inhibitors ALXN2040 and ALXN2050 are in the clinical phase II research stage and are used for the treatment of PNH, IgAN, C3G and other diseases.
- Biocryst’s factor D inhibitor BCX9930 is also in phase II clinical research for the treatment of PNH disease. Therefore, it is necessary to develop new small molecule inhibitors of the complement system Factor D, increase clinical research and verification, and use them in the treatment of various diseases caused by complement abnormalities to provide new treatment methods to meet clinical needs.
- the present invention provides compounds represented by formula (V) or pharmaceutically acceptable salts thereof,
- R 2 is selected from 5-6 membered heteroaryl and 8-10 membered heterocyclyl, which are independently optionally substituted by 1, 2 or 3 R b replaced;
- R 3 and R 4 are independently selected from H, F, Cl, Br, I and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 R d ;
- Each R 5 is independently selected from F, Cl, Br, I, NH 2 , OH and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 Re ;
- T 2 is selected from CH and N;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R a , each R d and each R e are independently selected from F, Cl, Br, I, NH 2 and OH;
- Each R b and each R c are independently selected from F, Cl, Br, I, NH 2 , OH, CN, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 alkylthio group, C 3-6 cycloalkyl group and 4-6 membered heterocycloalkyl group, the C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 alkylamino group, C 1 -4 alkylthio, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl are independently optionally substituted by 1, 2 or 3 F;
- n is selected from 0, 1, 2 and 3;
- n is selected from 1, 2 and 3;
- hetero of the 5-6-membered heteroaryl, 8-10-membered heterocyclyl and 4-6-membered heterocycloalkyl respectively represents 1, 2, 3 or 4 independently selected from -NH-, -O- , -S- and N heteroatoms or heteroatom groups.
- the present invention also provides compounds represented by formula (V) or pharmaceutically acceptable salts thereof,
- R 2 is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are independently optionally substituted by 1, 2 or 3 R b ;
- R 3 and R 4 are independently selected from H, F, Cl, Br, I and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 R d ;
- Each R 5 is independently selected from F, Cl, Br, I, NH 2 , OH and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 Re ;
- T 1 is selected from CH and N;
- T 2 is selected from CH and N;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R a , each R d and each R e are independently selected from F, Cl, Br, I, NH 2 and OH;
- Each R b and each R c are independently selected from F, Cl, Br, I, NH 2 , OH, CN, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 alkanes Thio group, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 alkylthio
- the base, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl are independently optionally substituted by 1, 2 or 3 F;
- n is selected from 0, 1, 2 and 3;
- n is selected from 1, 2 and 3;
- hetero of the 5-6-membered heteroaryl and 4-6-membered heterocycloalkyl groups respectively represents 1, 2, 3 or 4 hetero groups independently selected from -NH-, -O-, -S- and N. Atoms or groups of heteroatoms.
- the present invention also provides compounds represented by formula (II) or pharmaceutically acceptable salts thereof,
- R 2 is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are independently optionally substituted by 1, 2 or 3 R b ;
- R 3 and R 4 are independently selected from H, F, Cl, Br, I and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 R d ;
- Each R 5 is independently selected from F, Cl, Br, I, NH 2 , OH and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 Re ;
- T 1 is selected from CH and N;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R a , each R d and each R e are independently selected from F, Cl, Br, I, NH 2 and OH;
- Each R b and each R c are independently selected from F, Cl, Br, I, NH 2 , OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1- 4 alkylthio, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 Alkylthio, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 F;
- n is selected from 0, 1, 2 and 3;
- n is selected from 1, 2 and 3;
- hetero of the 5-6-membered heteroaryl and 4-6-membered heterocycloalkyl groups respectively represents 1, 2, 3 or 4 hetero groups independently selected from -NH-, -O-, -S- and N. Atoms or groups of heteroatoms.
- the present invention also provides compounds represented by formula (I) or pharmaceutically acceptable salts thereof,
- R 2 is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are independently optionally substituted by 1, 2 or 3 R b ;
- R 3 and R 4 are independently selected from H, F, Cl, Br, I and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 R d ;
- Each R 5 is independently selected from F, Cl, Br, I, NH 2 , OH and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 Re ;
- T 1 is selected from CH and N;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R a , each R d and each R e are independently selected from F, Cl, Br, I, NH 2 and OH;
- Each R b and each R c are independently selected from F, Cl, Br, I, NH 2 , OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1- 4 alkylthio, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 Alkylthio, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 F;
- n is selected from 0, 1, 2 and 3;
- hetero of the 5-6-membered heteroaryl and 4-6-membered heterocycloalkyl groups respectively represents 1, 2, 3 or 4 hetero groups independently selected from -NH-, -O-, -S- and N. Atoms or groups of heteroatoms.
- the present invention also provides compounds represented by formula (I) or pharmaceutically acceptable salts thereof,
- R 2 is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are independently optionally substituted by 1, 2 or 3 R b ;
- R 3 and R 4 are independently selected from H, F, Cl, Br, I and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 R d ;
- Each R 5 is independently selected from F, Cl, Br, I, NH 2 , OH and C 1-4 alkyl, and the C 1-4 alkyl is optionally substituted by 1, 2 or 3 Re ;
- T 1 is selected from CH and N;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R a , each R d and each R e are independently selected from F, Cl, Br, I, NH 2 and OH;
- Each R b and each R c are independently selected from F, Cl, Br, I, NH 2 , OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1- 4 alkylthio, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl, the C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 1-4 Alkylthio, C 3-6 cycloalkyl and 4-6 membered heterocycloalkyl are each independently optionally substituted by 1, 2 or 3 F;
- n is selected from 0, 1, 2 and 3;
- hetero of the 5-6-membered heteroaryl and 4-6-membered heterocycloalkyl groups respectively represents 1, 2, 3 or 4 hetero groups independently selected from -NH-, -O-, -S- and N. Atoms or groups of heteroatoms.
- each R b mentioned above is independently selected from F, Cl, Br, I, CH 3 and CF 3 , and other variables are as defined in the present invention.
- each R b mentioned above is independently selected from F, Cl, Br, I, CN, CH 3 and CF 3 , and other variables are as defined in the present invention.
- each of the above R c is independently selected from F, Cl, Br, I, CH 3 and CF 3 , and other variables are as defined in the present invention.
- the above R 2 is selected from pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl and
- the above R 2 is selected from pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thienyl, thiazolyl and oxazolyl , the pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thienyl, thiazolyl and oxazolyl groups are independently optionally substituted by 1, 2 or 3 R b substitutions, each R b and other variables are as defined in the present invention.
- the above-mentioned R 2 is selected from pyrimidinyl, pyridyl, pyrazinyl and pyridazinyl, and the pyrimidinyl, pyridyl, pyrazinyl and pyridazinyl are independently optionally substituted by 1, 2 or 3 R b substitutions, each R b and other variables are as defined in the present invention.
- the above-mentioned R 2 is selected from pyrimidinyl group, and the pyrimidine base is optionally substituted by 1, 2 or 3 R b , and each R b and other variables are as defined in the present invention.
- R 2 is selected from Other variables are as defined in the present invention.
- R 2 is selected from Other variables are as defined in the present invention.
- R 2 is selected from Other variables are as defined in the present invention.
- R 2 is selected from Other variables are as defined in the present invention.
- R 3 is selected from H and CH 3 , and other variables are as defined in the present invention.
- R 4 is selected from H and CH 3 , and other variables are as defined in the present invention.
- each R 5 mentioned above is independently selected from F, Cl, Br, I, NH 2 , OH, CH 3 and CF 3 , and other variables are as defined in the present invention.
- T 1 is selected from N, and other variables are as defined in the present invention.
- T 2 is selected from N, and other variables are as defined in the present invention.
- T 2 is selected from CH, and other variables are as defined in the present invention.
- the above-mentioned ring A is selected from pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl and pyrazolyl, and the pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl,
- the imidazolyl and pyrazolyl groups are each independently optionally substituted by 1, 2 or 3 R c , and each R c and other variables are as defined in the present invention.
- the above-mentioned ring A is selected from Other variables are as defined in the present invention.
- the above-mentioned ring A is selected from Other variables are as defined in the present invention.
- the above-mentioned ring A is selected from Other variables are as defined in the present invention.
- the above-mentioned ring A is selected from Other variables are as defined in the present invention.
- the above-mentioned ring A is selected from Other variables are as defined in the present invention.
- the above-mentioned compound or a pharmaceutically acceptable salt thereof, the compound thereof is selected from,
- T 1 , ring A, R 1 , R 2 , R 5 and n are as defined in the present invention.
- the above-mentioned compound or a pharmaceutically acceptable salt thereof, the compound thereof is selected from,
- the above-mentioned compound or a pharmaceutically acceptable salt thereof, the compound thereof is selected from,
- R 2 is selected from pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl and The pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl and Each independently optionally substituted by 1, 2 or 3 R b ;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R b is independently selected from F, Cl, Br, I, CN, CH 3 and CF 3 ;
- Each R c is independently selected from F, Cl, Br, I, CH 3 and CF 3 .
- the compound of the above formula (VI-1) or a pharmaceutically acceptable salt thereof is selected from,
- R 2 is selected from pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl and The pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl and Each independently optionally substituted by 1, 2 or 3 R b ;
- R 3 is selected from H, F, Cl, Br, I, CH 3 and CF 3 ;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R b is independently selected from F, Cl, Br, I, CN, CH 3 and CF 3 ;
- Each R c is independently selected from F, Cl, Br, I, CH 3 and CF 3 .
- the compound of the above formula (VI-1) or a pharmaceutically acceptable salt thereof is selected from,
- R 2 is selected from pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl and The pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl and Each independently optionally substituted by 1, 2 or 3 R b ;
- R 3 is selected from H, F, Cl, Br, I, CH 3 and CF 3 ;
- Ring A is selected from 5-6 membered heteroaryl groups, and the 5-6 membered heteroaryl groups are optionally substituted by 1, 2 or 3 R c ;
- Each R b is independently selected from F, Cl, Br, I, CN, CH 3 and CF 3 ;
- Each R c is independently selected from F, Cl, Br, I, CH 3 and CF 3 .
- the compound of the above formula (VI-1), (VI-1a) or (VI-1b) or a pharmaceutically acceptable salt thereof, the R 2 is selected from pyrimidinyl, pyridyl, pyridinyl, Azinyl, pyridazinyl, the pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl are independently optionally substituted by 1, 2 or 3 R b , and other variables are as defined in the present invention.
- the R 2 is selected from pyrimidinyl, and the pyrimidinyl Optionally substituted by 1, 2 or 3 R b , and other variables are as defined in the present invention.
- the R 2 is selected from Other variables are as defined in the present invention.
- the compound of the above formula (VI-1), (VI-1a) or (VI-1b) or a pharmaceutically acceptable salt thereof, the R 3 is selected from H and CH 3 , and other variables As defined herein.
- the compound of the above formula (VI-1), (VI-1a) or (VI-1b) or a pharmaceutically acceptable salt thereof, the ring A is selected from pyridyl, and the pyridyl Optionally substituted by 1, 2 or 3 Rc , other variables are as defined in the present invention.
- the compound of the above formula (VI-1), (VI-1a) or (VI-1b) or a pharmaceutically acceptable salt thereof, the ring A is selected from Other variables are as defined in the present invention.
- the present invention also provides the following compounds or pharmaceutically acceptable salts thereof,
- the above-mentioned compound or a pharmaceutically acceptable salt thereof, the compound thereof is selected from,
- the present invention also provides the use of the above-mentioned compounds or pharmaceutically acceptable salts thereof in the preparation of drugs for treating diseases related to Factor D inhibitors.
- the invention also provides the following synthesis methods:
- the compound of the present invention has a good combination with complement factor D, can significantly inhibit the activity of complement factor D, and has obvious inhibitory activity on the activation of the human serum bypass pathway; the compound of the present invention has excellent pharmacokinetic properties: long half-life, low clearance rate, plasma High exposure and bioavailability; excellent hepatic microsomal metabolic stability in various genera and excellent hepatic microsomal metabolic stability in human hepatocytes.
- the term "pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue. , without undue toxicity, irritation, allergic reactions, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- salts refers to salts of compounds of the present invention prepared from compounds having specific substituents found in the present invention and relatively non-toxic acids or bases.
- base addition salts can be obtained by contacting such compounds with a sufficient amount of base in pure solution or in a suitable inert solvent.
- acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
- Certain specific compounds of the present invention contain both basic and acidic functional groups and thus can be converted into either base or acid addition salts.
- the pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid groups or bases.
- such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the two.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereoisomers isomer, the (D)-isomer, the (L)-isomer, as well as their racemic mixtures and other mixtures, such as enantiomeric or diastereomerically enriched mixtures, all of which belong to the present invention. within the scope of the invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
- enantiomers or “optical isomers” refer to stereoisomers that are mirror images of each other.
- cis-trans isomers or “geometric isomers” refers to the inability of the double bonds or single bonds of the carbon atoms in the ring to rotate freely.
- diastereomer refers to stereoisomers whose molecules have two or more chiral centers and are in a non-mirror image relationship between the molecules.
- use wedge-shaped solid line keys and wedge-shaped dotted keys Represents the absolute configuration of a three-dimensional center, using straight solid line keys and straight dotted keys Indicate the relative configuration of the three-dimensional center, using wavy lines Represents wedge-shaped solid line key or wedge-shaped dotted key or use tilde Represents a straight solid line key or straight dotted key
- tautomer or “tautomeric form” means that at room temperature, isomers with different functional groups are in dynamic equilibrium and can quickly convert into each other. If tautomers are possible (eg in solution), a chemical equilibrium of tautomers can be achieved.
- proton tautomers also called proton transfer tautomers
- proton migration tautomers include interconversions by proton migration, such as keto-enol isomerization and imine-enol isomerization. Amine isomerization.
- Valence tautomers include interconversions through the reorganization of some bonding electrons.
- keto-enol tautomerization is the tautomerization between pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
- the terms "enriched in an isomer,”"enantiomericallyenriched,””enriched in an enantiomer,” or “enantiomerically enriched” refer to one of the isomers or enantiomers.
- the content of the enantiomer is less than 100%, and the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
- isomeric excess or “enantiomeric excess” refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, then the isomer or enantiomeric excess (ee value) is 80% .
- the compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound.
- compounds can be labeled with radioactive isotopes such as tritium ( 3H ), iodine-125 ( 125I ) or C-14 ( 14C ).
- deuterated drugs can be replaced by heavy hydrogen to form deuterated drugs. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs can reduce side effects and increase drug stability. , enhance efficacy, extend drug biological half-life and other advantages. All variations in the isotopic composition of the compounds of the invention, whether radioactive or not, are included within the scope of the invention.
- substituted means that any one or more hydrogen atoms on a specific atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence state of the specific atom is normal and the substituted compound is stable.
- oxygen it means that two hydrogen atoms are replaced.
- Oxygen substitution does not occur on aromatic groups.
- optionally substituted means that it may or may not be substituted. Unless otherwise specified, the type and number of substituents may be arbitrary on the basis of chemical achievability.
- any variable e.g., R
- its definition in each instance is independent.
- said group may optionally be substituted by up to two R's, with independent options for R in each case.
- substituents and/or variants thereof are permitted only if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- the direction of connection is arbitrary, for example, The middle linking group L is -MW-.
- -MW- can be connected to ring A and ring B in the same direction as the reading order from left to right. You can also connect ring A and ring B in the opposite direction to the reading order from left to right.
- any one or more sites of the group can be connected to other groups through chemical bonds.
- connection mode of the chemical bond is non-positioned and there are H atoms at the connectable site, when the chemical bond is connected, the number of H atoms at the site will be reduced correspondingly with the number of connected chemical bonds and become the corresponding valence. group.
- the chemical bond connecting the site to other groups can be a straight solid line bond straight dashed key or wavy lines express.
- C 1-4 alkyl is used to mean a straight or branched chain saturated hydrocarbon group consisting of 1 to 4 carbon atoms.
- the C 1-4 alkyl group includes C 1-2 , C 1-3 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent ( Such as methine).
- Examples of C 1-4 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl , s-butyl and t-butyl), etc.
- C 1-4 alkoxy by itself or in combination with another term, means those alkyl groups containing 1 to 4 carbon atoms that are attached to the remainder of the molecule through an oxygen atom.
- the C 1-5 alkoxy group includes C 1-2 , C 1-3 , C 2-3 , C 2-4 , C 3-4 , C 3 and C 4 alkoxy groups, etc. It can be monovalent, bivalent or polyvalent.
- Examples of C 1-4 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy Oxygen, s-butoxy and t-butoxy), etc.
- C 1-4 alkylthio by itself or in combination with another term, means those alkyl groups containing 1 to 4 carbon atoms that are attached to the remainder of the molecule through a sulfur atom.
- the C 1-5 alkylthio group includes C 1-2 , C 1-3 , C 2-3 , C 2-4 , C 3-4 , C 3 and C 4 alkylthio groups, etc. It can be monovalent, bivalent or polyvalent.
- Examples of C 1-4 alkylthio groups include, but are not limited to, -SCH 3 , -SCH 2 CH 3 , -SCH 2 CH 2 CH 3 , -SCH 2 (CH 3 ) 2 , and the like.
- C 1-4 alkylamino by itself or in combination with another term, means those alkyl groups containing 1 to 4 carbon atoms that are attached to the remainder of the molecule through a nitrogen atom.
- the C 1-4 alkylamino group includes C 1-2 , C 1-3 , C 2-3 , C 2-4 , C 3-4 , C 3 and C 4 alkylamino groups, etc. It can be monovalent, bivalent or polyvalent.
- Examples of C 1-4 alkylamino include, but are not limited to, -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -NHCH 2 CH 2 CH 3 , -NHCH 2 (CH 3 ) 2 and the like.
- C 3-6 cycloalkyl by itself or in combination with other terms respectively represents a saturated monocyclic hydrocarbon group composed of 3 to 6 carbon atoms, and the C 3-6 cycloalkyl group includes C 3-5 , C 4-5 and C 5-6 cycloalkyl, etc.; it can be monovalent, divalent or multivalent.
- Examples of C 3-6 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- 4-6 membered heterocycloalkyl by itself or in combination with other terms means a saturated monocyclic group consisting of 4 to 6 ring atoms, with 1, 2, 3 or 4 ring atoms. are heteroatoms or heteroatom groups independently selected from O, S, NH and N, and the remainder are carbon atoms, in which the nitrogen atoms are optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S( O) p , p is 1 or 2). Furthermore, in the case of the "4-6 membered heterocycloalkyl", a heteroatom may occupy the attachment position of the heterocycloalkyl to the rest of the molecule.
- the 3-6-membered heterocycloalkyl group includes 4-5-membered, 5-6-membered, 4-membered, 5-membered and 6-membered heterocycloalkyl groups, etc. It can be monovalent, bivalent or polyvalent.
- Examples of 4-6 membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl ( Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2- Piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl, 4-morpholinyl, etc.), Dioxanyl, dithianyl, isoxazolidinyl, isothiazolidin
- the term "8-10 membered heterocyclyl" by itself or in combination with other terms refers to a saturated or partially unsaturated cyclic group consisting of 8 to 10 ring atoms, of which 1, 2, 3, 4 or 5 ring atoms are heteroatoms or heteroatom groups independently selected from O, S, NH and N, and the remainder are carbon atoms, wherein the carbon atoms are optionally oxidized (i.e. CO), and the nitrogen atoms are optionally quaternized. ation, nitrogen and sulfur heteroatoms may optionally be oxidized (i.e. NO and S(O) p , p is 1 or 2).
- the 8-10-membered heterocyclic groups include 8-membered, 9-membered and 10-membered heterocyclic groups, etc.
- the 8-10 membered heterocyclyl group includes single rings and polycyclic rings, such as spiro rings, paracyclic rings, and bridged rings. It can be monovalent, bivalent or polyvalent. Examples of 8-10 membered heterocyclyl groups include, but are not limited to wait.
- the terms “5-6 membered heteroaromatic ring” and “5-6 membered heteroaryl” in the present invention can be used interchangeably, and the term “5-6 membered heteroaryl” by itself or in combination with other terms means respectively A monocyclic group with a conjugated ⁇ electron system composed of 5 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms.
- the nitrogen atoms are optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2).
- a 5-6 membered heteroaryl group can be attached to the rest of the molecule through a heteroatom or a carbon atom.
- the 5-6 membered heteroaryl group includes 5-membered heteroaryl group and 6-membered heteroaryl group.
- Examples of the 5-membered heteroaryl include but are not limited to pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl) etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl) base, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2, 4-triazoly
- 6-membered heteroaryl examples include, but are not limited to, pyridyl (including 2-pyridyl, 3-pyridyl, 4-pyridyl, etc.), pyrazinyl, pyrazinyl or pyrimidinyl (including 2-pyrimidinyl) and 4-pyrimidinyl, etc.) etc.
- C n-n+m or C n -C n+m includes any specific case of n to n+m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4 , C5 , C6 , C7 , C8 , C9 , C10 , C11 , and C12 , also include any range from n to n+m, for example, C1-12 includes C1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 , etc.; similarly, n yuan to n The +m member indicates that the number of atoms in the ring is n to n+m.
- a 3-12 membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, and a 9-membered ring.
- 3-membered ring includes 3-6-membered ring, 3-9-membered ring, 5-6-membered ring ring, 5-7 membered ring, 6-7 membered ring, 6-8 membered ring, and 6-10 membered ring, etc.
- leaving group refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction, such as a nucleophilic substitution reaction.
- representative leaving groups include triflate; chlorine, bromine, iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonate Ester, etc.; acyloxy group, such as acetoxy group, trifluoroacetoxy group, etc.
- protecting group includes, but is not limited to, "amino protecting group", “hydroxy protecting group” or “thiol protecting group”.
- amino protecting group refers to a protecting group suitable for preventing side reactions at the nitrogen position of an amino group.
- Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc) ; Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); Arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS) and so on.
- acyl such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as
- hydroxyl protecting group refers to a protecting group suitable for preventing hydroxyl side reactions.
- Representative hydroxyl protecting groups include, but are not limited to: alkyl groups, such as methyl, ethyl, and tert-butyl groups; acyl groups, For example, alkanoyl (such as acetyl); arylmethyl, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl) Methyl, DPM); silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); tert-butyldiphenylsilyl (TBDPS) and so on.
- alkyl groups such as methyl, ethyl, and tert-butyl groups
- acyl groups For example, alkanoyl (such as acetyl);
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and methods well known to those skilled in the art. Equivalent alternatives and preferred embodiments include, but are not limited to, embodiments of the present invention.
- the structure of the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention involves the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art.
- single crystal X-ray diffraction uses a Bruker D8 venture diffractometer to collect diffraction intensity data on the cultured single crystal.
- the light source is CuK ⁇ radiation.
- the scanning method is: After scanning and collecting relevant data, the direct method (Shelxs97) is further used to analyze the crystal structure, and the absolute configuration can be confirmed.
- PE represents petroleum ether
- EA or EtOAc represents ethyl acetate
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and methods well known to those skilled in the art. Equivalent alternatives and preferred embodiments include, but are not limited to, embodiments of the present invention.
- the solvent used in the present invention is commercially available.
- Compounds are named according to conventional naming principles in the field or use For software naming, commercially available compounds adopt supplier catalog names.
- FIG. 1 Protein binding pattern diagram of compound A and complement factor D.
- the molecular docking process was performed using Maestro Performed in Glide SP [1] and default options.
- the crystal structure of the complex of complement factor D and a selective small molecule inhibitor (PDB: 5NB7) was selected as the docking template.
- PDB selective small molecule inhibitor
- LigPrep was used to generate the three-dimensional structure of the molecule and energy minimization was performed [3] , and the confgen module was used to sample the small molecule conformation.
- ligands in 5NB7 The molecule serves as the center of mass and generates a side length of of cube docking mesh.
- Place reference compounds during molecular docking Analyze the interaction type between the protein receptor and the ligand, analyze the interaction type between the protein receptor and the ligand, and then select and save a reasonable docking conformation based on the calculated docking score and binding mode.
- compound N-6 (200g, 454.98mmol) was dissolved in toluene (1200mL), lithium triethylborohydride (1M tetrahydrofuran solution, 545.98mL) was added dropwise at -78°C, and the reaction was carried out at -78°C for 2 hours. .
- Diisopropylethylamine (321.94g, 2.49mol) and trifluoroacetic anhydride (142.69g, 679.36mmol) were added dropwise, and the reaction was carried out at -65°C for 2 hours, then returned to 25°C for 14 hours. Add 1500 mL of water to quench, and then extract with 2000 mL of ethyl acetate.
- reaction solution was concentrated under reduced pressure, then 20 mL of dichloromethane was added, and washed with saturated ammonium chloride solution (15 mL ⁇ 3); the obtained organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- the crude product was purified by high performance liquid chromatography (column: C18 100 ⁇ 40mm; mobile phase: phase A water (trifluoroacetic acid), phase B is acetonitrile, gradient B%: 26%-56%), and the resulting sample solution After concentration under reduced pressure, adjust the pH to 7-8 with saturated sodium bicarbonate solution, extract with dichloromethane (5mL ⁇ 3), wash the combined organic phase with saturated brine (10mL), dry over anhydrous sodium sulfate, filter and concentrate to obtain Compound 7.
- MS (ESI): m/z 638.1/640.1[M+H] + .
- the compound of the present invention has obvious inhibitory activity on the activation of human serum bypass pathway.
- Injection (IV) The solvent is 10% DMSO/10% solution/80% H 2 O, the concentration is 0.20 mg/mL, and the dosage is 1 mg/kg;
- Sample collection 0.025mL of blood sample was collected from the saphenous vein puncture of the experimental animals at each time point, and the actual blood collection time was recorded. All blood samples were added into commercial EDTA-K2 anticoagulant tubes with a specification of 1.5 mL (supplier is Jiangsu Kangjian Medical Products Co., Ltd.). After blood samples are collected, within half an hour, centrifuge at 4°C and 3200g for 10 minutes to absorb the supernatant plasma, quickly place it in dry ice, and store it in a -80°C refrigerator for LC-MS/MS analysis.
- mice pharmacokinetic study show that the compound of the present invention has a long half-life, high plasma exposure, high bioavailability, and It has excellent pharmacokinetic properties.
- Sample collection About 0.250 mL of blood samples were collected from jugular vein puncture of experimental animals at each time point, and the actual blood collection time was recorded. All blood samples were added into commercial EDTA-K2 anticoagulant tubes with a specification of 1.5 mL (supplier is Jiangsu Kangjian Medical Products Co., Ltd.). After blood samples are collected, centrifuge at 4°C and 3200g for 10 minutes to absorb the supernatant plasma, quickly place it in dry ice, and store it in a -80°C refrigerator for LC-MS/MS analysis.
- Liver microsomes Human and animal microsomes were purchased from Corning or Xenotech and stored in a -80°C refrigerator.
- NADPH Reduced nicotinamide adenine dinucleotide phosphate
- Control compounds testosterone, diclofenac, propafenone.
- Working concentration preparation dilute to 100 ⁇ M with 100% acetonitrile
- T60 incubation plate Prepare two 96-well incubation plates, named T60 incubation plate and NCF60 incubation plate respectively.
- microsomal working solution live microsomal protein concentration is 0.56 mg/mL
- test product or control compound working solution After the pre-incubation, add 5 ⁇ L of test product or control compound working solution to the T60 incubation plate and NCF60 incubation plate respectively, and mix well.
- the final concentration of the compound, testosterone, diclofenac and propafenone in the reaction is 1 ⁇ M
- the concentration of liver microsomes is 0.5 mg/mL
- the final concentration of DMSO and acetonitrile in the reaction system 0.01% (v/v) and 0.99% (v/v) respectively.
- stop solution acetonitrile solution containing 200ng/mL tolbutamide and 200ng/mL labetalol
- the compound of the present invention has excellent metabolic stability in various hepatic microsomes.
- the metabolic stability of the compound of the present invention in human liver cells was investigated.
- the test product is 1 ⁇ M
- the final concentration of liver cells is 0.5 ⁇ 10 6 cells/mL
- the final concentration of total organic solvents is 0.96%
- the final concentration of DMSO is 0.1%.
- the compound of the present invention has a medium to slow clearance rate in human liver cells and has excellent metabolic stability.
Abstract
L'invention concerne une série de composés azabicyclo difluoro-substitués et leurs utilisations, et spécifiquement un composé représenté par la formule (V) et un sel pharmaceutiquement acceptable de celui-ci.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210800800.6 | 2022-07-06 | ||
CN202210800800 | 2022-07-06 | ||
CN202210917090 | 2022-08-01 | ||
CN202210917090.5 | 2022-08-01 | ||
CN202211282922 | 2022-10-19 | ||
CN202211282922.7 | 2022-10-19 | ||
CN202310066225.6 | 2023-01-17 | ||
CN202310066225 | 2023-01-17 | ||
CN202310193538 | 2023-03-02 | ||
CN202310193538.8 | 2023-03-02 | ||
CN202310365727 | 2023-04-04 | ||
CN202310365727.9 | 2023-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024008121A1 true WO2024008121A1 (fr) | 2024-01-11 |
Family
ID=89454429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/105913 WO2024008121A1 (fr) | 2022-07-06 | 2023-07-05 | Composés azabicyclo difluoro-substitués et leurs utilisations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024008121A1 (fr) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106413707A (zh) * | 2014-02-25 | 2017-02-15 | 艾其林医药公司 | 用于治疗补体介导的疾病的酰胺化合物 |
CN108024992A (zh) * | 2015-08-26 | 2018-05-11 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环化合物 |
WO2019227102A1 (fr) * | 2018-05-25 | 2019-11-28 | Achillion Pharmaceuticals, Inc. | Biomarqueurs de néphropathie associés à la voie alternative du complément |
CN110603252A (zh) * | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
WO2020041301A1 (fr) * | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément |
CN111163767A (zh) * | 2017-08-02 | 2020-05-15 | 艾其林医药公司 | 治疗阵发性睡眠性血红蛋白尿症的治疗方案 |
WO2021168320A1 (fr) * | 2020-02-20 | 2021-08-26 | Achillion Pharmaceuticals, Inc. | Composés hétéroaryle pour le traitement de troubles médiés par le facteur d du complément |
WO2021183555A1 (fr) * | 2020-03-10 | 2021-09-16 | Achillion Pharmaceuticals, Inc. | Dépôt de médicament oculaire pour troubles à médiation par le complément |
WO2021202977A1 (fr) * | 2020-04-03 | 2021-10-07 | Biocryst Pharmaceuticals, Inc. | Pyrrolopyrimidine amines en tant qu'inhibiteurs du complément |
-
2023
- 2023-07-05 WO PCT/CN2023/105913 patent/WO2024008121A1/fr unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106413707A (zh) * | 2014-02-25 | 2017-02-15 | 艾其林医药公司 | 用于治疗补体介导的疾病的酰胺化合物 |
CN108024992A (zh) * | 2015-08-26 | 2018-05-11 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环化合物 |
CN110603252A (zh) * | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
CN111163767A (zh) * | 2017-08-02 | 2020-05-15 | 艾其林医药公司 | 治疗阵发性睡眠性血红蛋白尿症的治疗方案 |
WO2019227102A1 (fr) * | 2018-05-25 | 2019-11-28 | Achillion Pharmaceuticals, Inc. | Biomarqueurs de néphropathie associés à la voie alternative du complément |
WO2020041301A1 (fr) * | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément |
WO2021168320A1 (fr) * | 2020-02-20 | 2021-08-26 | Achillion Pharmaceuticals, Inc. | Composés hétéroaryle pour le traitement de troubles médiés par le facteur d du complément |
WO2021183555A1 (fr) * | 2020-03-10 | 2021-09-16 | Achillion Pharmaceuticals, Inc. | Dépôt de médicament oculaire pour troubles à médiation par le complément |
WO2021202977A1 (fr) * | 2020-04-03 | 2021-10-07 | Biocryst Pharmaceuticals, Inc. | Pyrrolopyrimidine amines en tant qu'inhibiteurs du complément |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022222995A1 (fr) | Composé picolinamide | |
WO2020239076A1 (fr) | DÉRIVÉS DE PYRIDAZINONE CONSTITUANT DES AGONISTES DU RÉCEPTEUR DE LA THYROXINE DE TYPE β ET LEUR UTILISATION | |
CN112771045B (zh) | 喹啉并吡咯烷-2-酮类衍生物及其应用 | |
TW202128715A (zh) | 作為erk抑制劑的螺環類化合物及其應用 | |
WO2019185026A1 (fr) | Dérivés glucosidiques agissant en tant qu'inhibiteurs de sglt, et leur utilisation | |
WO2021238999A1 (fr) | Composé de fluoropyrrolopyridine et son application | |
CN113874379B (zh) | 作为Cdc7抑制剂的四并环类化合物 | |
KR102500569B1 (ko) | 선택적 btk 키나제 억제제로서의 피라졸로피리딘계 화합물 | |
WO2024008121A1 (fr) | Composés azabicyclo difluoro-substitués et leurs utilisations | |
WO2023217045A1 (fr) | Dérivé de fluoroquinoxalinone pour l'inhibition selective de parp1 | |
WO2021129817A1 (fr) | Composé à base de pyrimidine ayant un effet inhibiteur de la cétohexokinase (chk) | |
WO2021098691A1 (fr) | Composés de pyrrolotriazine agissant comme inhibiteur de mnk | |
CN114761407A (zh) | 作为高选择性ros1抑制剂的化合物及其应用 | |
WO2020063965A1 (fr) | Dérivé de pyrazolopyrimidine en tant qu'inhibiteur de trk sélectif | |
WO2022166721A1 (fr) | Dérivés cycliques fusionnés contenant du 1,4-oxazépane | |
WO2023001069A1 (fr) | Composés amides macrocycliques et leur application | |
WO2022156765A1 (fr) | Composé tricyclique lié à la pyrazolopyrazine et son application | |
CN113811530B (zh) | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 | |
CN113166055A (zh) | 雌激素受体拮抗剂 | |
JP2022521673A (ja) | Pd-l1免疫調整剤であるフルオロビニルベンズアミド化合物 | |
WO2023241618A1 (fr) | Composés aminopyrimidines et leur utilisation | |
TWI825800B (zh) | 亞磺醯亞胺類化合物及其應用 | |
WO2023208127A1 (fr) | Composé bicyclique substitué par hétéroaryle et son utilisation | |
WO2021098810A1 (fr) | Composé utilisé comme modulateur sélectif du récepteur des androgènes | |
WO2023237041A1 (fr) | Composé ester d'acide carboxylique aromatique substitué bicyclique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23834888 Country of ref document: EP Kind code of ref document: A1 |